Verizon Communications Inc.
BAC.DE News Today: Stay Updated with the Latest Verizon Communications Inc. News in Real Time
Find BAC.DE news now at Meyka AI. Stay informed with the latest Verizon Communications Inc. stocks updates, including price news, market analysis, and expert insights.
4075.T Brains Technology (JPX) +12.88% on volume spike 13 Mar 2026: watch earnings
4075.T stock jumps on a volume surge to JPY 1613.00 on 13 Mar 2026; analysts watch earnings and valuation
IDFCFIRSTB.NS Stock Today: March 13 Probe Widens in Rs 590 Crore Scam
IDFC First Bank scam: Haryana ACB arrests 11, freezes 100+ accounts in a ₹590 crore case; Chandigarh FIR flags ₹75 crore CREST accounts fraud. Stock at ₹62.57 (-5.43%).
RCAT Red Cat NASDAQ pre-market 13 Mar 2026: $16.16 before March 18 earnings
RCAT stock trades at $16.16 pre-market on 13 Mar 2026 ahead of March 18 earnings; outlook and Meyka AI forecast included
Oncolys (4588.T) -16.48% to JPY 2702 on 13 Mar 2026 Mkt closed: watch catalysts
4588.T stock fell 16.48% to JPY 2,702 on 13 Mar 2026. Volume 2,399,900. Short-term support and analyst view for JPX trading
Titan Medical TMD.TO (TSX) up 2,150% pre-market 13 Mar 2026: volume-driven move
TMD.TO stock jumps pre-market on heavy volume; read our analysis, Meyka AI grade, and forecast vs CAD 1.125
VIVE (Viveve Medical) NASDAQ pre-market up 19,900% on 13 Mar 2026: top gainer insight
VIVE stock jumps pre-market to **$0.0002** on Mar 13 2026. Quick analysis, Meyka grade, and forecast for VIVE stock
Leerink Maintains Outperform on BBIO, BridgeBio Pharma, Inc. March 12, 2026
Leerink maintains Outperform on BBIO on March 12, 2026 — analysis of implications and Meyka grade for BBIO analyst rating
DMN stock at $0.0017 pre-market: heavy 2.23B volume signals most-active trade
DMN stock trades at $0.0017 pre-market with 2.23B volume. Our DMN stock analysis offers grades, valuation, and a 12-month DMN stock forecast
Jefferies Maintains Buy on BioMarin Pharmaceutical Inc. (BMRN) March 2026
Jefferies maintains Buy on BioMarin. Read the BMRN analyst rating update, implications, Meyka Grade B+ and market context